

REMARKS


The Examiner has objected to the applicants' failure to identify a species from claims 3-7, 9, 13 and 15 for further prosecution and identify all claims readable thereon.

Applicants hereby identify tazarotene as the prodrug and tazarotenic acid as the drug. Tazarotene is an ester of tazarotenic acid. Both compounds are retinoids and are sulfur-based. (See formula 1 on page 11 of the present specification.) Therefore, claims 3, 4 and 6-9 read on this species. (It is not understood why the Examiner is not including claim 8 in his action, since tazarotene in claim 8 is the prodrug of tazarotenic acid, which is the active drug of claim 7.)

If the Examiner wishes to discuss this response, he is invited to call the attorney of record at the telephone number given below.

The undersigned is an attorney of record.

Date: June 16, 2008

By:   
ROBERT J. BARAN  
Registration No. 25,806

Please direct all correspondence to:  
Robert J. Baran, Esq.  
Attorney of Record  
2372 S.E. Bristol Street, Suite B  
Newport Beach, California 92660-0755

Cellphone (714) 394-3654  
Telephone: (949) 851-1105  
Telecopier: (949) 752-1925



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS TRANSMITTAL IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE FOR FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: MAIL STOP AMENDMENT-FEE, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 ON THE DATE INDICATED BELOW. DEPOSITOR'S NAME:

Signature: \_\_\_\_\_

*RJB*

Date: June 16, 2008